Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Stephen Eck, M.D., Ph.D. as Chief Medical Officer (CMO) at Immatics US, Inc. (Houston, Texas), effective immediately.
Immatics Appoints Stephen Eck as Chief Medical Officer US
Crescendo Biologics Ltd. Raises $70 Million (€57 Million) in Series B Financing
Crescendo Biologics Ltd (Crescendo), announced today that it has completed a $70 million (€57 million) Series B financing.
The funds will be used to advance the development of its lead programme, CB307, which stimulates local activation of tumour-specific T-cells, into the clinic and further expand its internal pipeline of products.
Topas Therapeutics and Boehringer Ingelheim Sign Multi-Year Collaboration and Option Agreement
Topas Therapeutics GmbH (Topas), today announced that it has signed a multi-year agreement with Boehringer Ingelheim to collaborate in the field of antigen-specific tolerance induction with an initial focus on virus-based delivery vectors that confer novel therapeutics to patients.